5 Key Takeaways | Best Practices in Patent Drafting: Addressing 112 and Enablement after Amgen
In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit affirmed the district court decision that upheld the validity of the Allergan patents relating to LumiganĀ® 0.01% glaucoma eye drops against obviousness, written...more
In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit affirmed the district court decision that upheld the validity of the Allergan patents relating to LumiganĀ® 0.01% glaucoma eye drops. This decision shows that it is still...more